- The PRIMED study found a way to reduce treatment-related side effects among participants, decreasing dose reductions, treatment interruptions, and permanent discontinuations.
- The strategic alliance between MEDSIR and Oncoclínicas has enabled the company to present 13 studies at the 2024 ASCO Annual Meeting.
CHICAGO, June 2, 2024 /PRNewswire/ -- Leading international medical research company, MEDSIR, today announced the results of the recent PRIMED clinical trial... (continue reading...)
-Trial-in-Progress poster provides overview on PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with recurrent/metastatic HNSCC-
LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 2, 2024 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the presentation of a Trial-in-Progress poster at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO... (continue reading...)
LAGOS, Nigeria, June 2, 2024 /PRNewswire/ -- The Federal Government through the Nigeria Data Protection Commission (NDPC) has granted a licence to the Institute of Information Management (IIM) to conduct examinations and certify data protection professionals for global competitiveness.
The National Commissioner of NDPC, Dr. Vincent Olatunji, who said... (continue reading...)
- Results of survey will be presented by Adrian Dobs, M.D., Professor of Medicine and Oncology, The Johns Hopkins School of Medicine, and Sandeep Dhindsa, M.B.B.S., Director of Division of Endocrinology, Diabetes and Metabolism, St. Louis University School of Medicine, at ENDO 2024 in Boston on June 2.
BUFFALO GROVE, Ill., June 2, 2024 /PRNewswire/ -- Tolmar Inc., a fully integrated pharmaceutical company, today announced results from a landmark survey of more than... (continue reading...)
GUANGZHOU, China, June 2, 2024 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, will present a poster at the 2024 ASCO Annual Meeting entitled "Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors," that highlights clinical data for the potential best-in-class efficacy... (continue reading...)
More PRNewswire
View Older Stories-
Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
-
Vention to democratize industrial automation using NVIDIA AI technologies
-
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
-
Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
-
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
-
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
-
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
-
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
-
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
-
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
-
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
-
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a La
-
LENNY KRAVITZ ROCKS OUT AT THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®
-
Sun Bum Makes SPF Waves in Miami with its Largest Ever Beach Hangout for Skin Cancer Awareness Month
-
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
-
BIOHACKING CONFERENCE ANNOUNCES STEMREGENⓇ WILL RETURN AS TITLE SPONSOR FOR 2025
-
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting
-
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Upd
-
Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
-
Taseko Announces that Operations at its Gibraltar Mine have been Suspended
-
PHILADELPHIA KICKS OFF PRIDE MONTH BY SETTING THE FIRST-EVER GUINNESS WORLD RECORDS™ FOR THE "LARGEST ATTENDANCE AT DRAG QUEEN STORY TIME"
-
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!
-
ICECO Launches APL35 on Indiegogo - The World's Lightest Aluminum Dual-Zone Freezer
-
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple
-
American Cancer Society and American Society of Clinical Oncology Unite to Create One of the Largest and Most Comprehensive Online Sources of Credible Cancer Information
-
Beverly Hills MD Celebrates Its 10th Anniversary
-
Hyundai Motor America Reports May 2024 Sales
-
Vincent Todd Announces the Introduction of Todd Agriscience
-
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
-
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
-
BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
-
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
-
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
-
James Avery Artisan Jewelry Opens New Store at Westover Marketplace
-
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemo
-
ZEEKR Announces May 2024 Delivery Update
-
ALL-TIME BEST MONTHLY SALES FOR THE KIA EV9 AND SPORTAGE SUVs LEAD KIA AMERICA TO SECOND BEST SALES MONTH IN COMPANY HISTORY IN MAY
-
'A Fu, the hutong gentleman'
-
HTX Ventures Invests in Babylon to Advance Trustless Bitcoin Staking
-
Skymizer Launches Groundbreaking LLM Accelerator IP for on-device LLM Inferencing, EdgeThought, the game-changer in on-device GenAI era.
-
Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024
-
Hamamatsu Photonics completes the acquisition of NKT Photonics A/S
-
Discover the World expands relationship with South African Airways adding Key European Markets
-
West Fraser Releases 2023 Sustainability Report
-
Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
-
Babyganics and Nikki Reed Launch 'Oops! I Forgot It Again' To Help Parents Prepare for Summer
-
AZORES AIRLINES OFFERS NEW ROUTES STARTING IN JUNE
-
Local Middle School Students win $5,000 Game Creator Scholarship--to be presented on June 3rd at Eckstein Middle School
